奈达铂联合多西他赛治疗老年晚期非小细胞肺癌的疗效观察

Efficacy of Nedaplatin Combined with Docetaxel in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

目的分析对老年晚期非小细胞肺癌患者使用奈达铂联合多西他赛治疗的临床效果。方法入组参与研究的患者均确诊为老年晚期非小细胞肺癌72例,均为2016年2月至2018年2月入院接受治疗,依据数字表法分组,对照组及观察组各36例。对照组使用顺铂联合多西他赛治疗,观察组用奈达铂联合多西他赛治疗,治疗后对所得疗效进行对比。结果治疗后观察组血清可溶性白细胞介素2受体(IL-2R)、糖类抗原19-9(CA19-9)、血管内皮生长因子(VEGF)、血清癌胚抗原(CEA)分别为(275.41±21.36)U/mL、(50.41±5.37)U/mL、(135.24±14.38)pg/mL(、5.93±1.21)μg/L,与对照组[(352.23±14.37)U/mL(、72.43±5.52)U/mL(、202.31±7.14)pg/mL(、10.18±2.14)μg/L]比较,差异有统计学意义(P<0.05)。随访3年两组生存率、无进展生存时间以及平均生存时间,观察组与对照组相比均显著更长(P<0.05)。结论使用奈达铂联合多西他赛对老年晚期非小细胞肺癌患者进行治疗预后效果更佳,有利于延长患者生存时间,提高患者生存率。

Objective To analyze the clinical effect of nedaplatin combined with docetaxel in elderly patients with advanced non-small cell lung cancer.Methods Seventy-two elderly patients with advanced non-small cell lung cancer were enrolled in the study.They were all hospitalized from February 2016 to February 2018.They were divided into control group and observation group with 36 cases in each group.The control group was treated with cisplatin combined with docetaxel,and the observation group was treated with nedaplatin combined with docetaxel.Results After treatment,the serum soluble interleukin-2 receptor,carbohydrate antigen 19-9,vascular endothelial growth factor and serum carcinoembryonic antigen in the observation group were(275.41±21.36)U/mL,(50.41±5.37)U/mL,(135.24±14.38)pg/mL and(5.93±1.21)μg/L,respectively,which were significantly different from those in the control group[(352.23±14.37)U/mL,(72.43±5.52)U/mL,(202.31±7.14)pg/mL,(10.18±2.14)μg/L](P<0.05).After 3 years of follow-up,the survival rate,progression free survival time and average survival time of the two groups were significantly longer in the observation group than in the control group(P<0.05).Conclusion Nedaplatin combined with docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer has better prognosis,is conducive to prolong the survival time of patients,improve the survival rate of patients.